Biomicroscopic and Histopathologic Considerations Regarding the Feasibility of Surgical Excision of Subfoveal Neovascular Membranes

Jd, Gass

doi:10.1016/s0002-9394(14)72951-4

Cited by 319 publications

(119 citation statements)

References 15 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…He introduced the terms type I CNV to describe new vessels developing in the sub-RPE space, and type II for new vessels developing above the RPE. 45 Following the advent of multimodal imaging, especially SD-OCT, Freund et al 46 proposed a shift in the classification of Eye neovascularization towards Gass' histologic classification. They added a third entity, intraretinal neovascularization, also known as RAP, and lesions with more than one neovascular type (mixed neovascularization).…”

Section: Eyementioning

confidence: 99%

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

Gemenetzi

Lotery

Patel

2016

Eye

104

View full text Add to dashboard Cite

Anti-vascular endothelial growth factor (VEGF) intravitreal agents are the only successful treatment for wet age-related macular degeneration (AMD). However, there are emerging signals that anti-VEGF treatment can potentially increase development of geographic atrophy (GA). Histopathologic, animal, and clinical studies support this hypothesis although direct proof of a relationship between GA and use of anti-VEGF agents in neovascular AMD is not yet established. This review presents current evidence supporting an association between anti-VEGF therapy and progression of geographic atrophy. The need of exploring alternative methods of treating AMD is indirectly but clearly emphasized.

show abstract

Section: Eyementioning

confidence: 99%

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

Gemenetzi

Lotery

Patel

2016

Eye

104

View full text Add to dashboard Cite

show abstract

“…Table 1 depicts the demographic features of the 36 eyes of 27 patients. The mean age at presentation was 12.7±3.0 years (range, [7][8][9][10][11][12][13][14][15][16][17]. Seventeen of the 27 (63%) patients were male.…”

Section: Resultsmentioning

confidence: 99%

“…8 All these factors may make the natural course, prognosis, and treatment outcomes more favorable among young subjects. 9 Further, several etiological aspects related to CNV in children and adolescents remain imprecise. Although causes of CNV in young patients have been reviewed before, [10][11][12] there are no large studies comparing the relative frequency of the causes in subjects below 18 years of age.…”

Section: Introductionmentioning

confidence: 99%

Choroidal neovascularization in 36 eyes of children and adolescents

Rishi

Gupta

Rishi

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To describe the clinical features and outcomes among eyes with choroidal neovascularization (CNV) in children and adolescents. Methods A total of 36 eyes of 27 patients o18 years of age diagnosed with CNV between January 1978 and December 2008 were retrospectively reviewed. CNV was clinically diagnosed in all patients and its presence was confirmed by fundus fluorescein angiography (FFA). A total of 19 eyes underwent treatment. Anatomical outcome was evaluated as regressed/ persistent/recurrent CNV. Snellen's values for best corrected visual acuity (BCVA) were converted to logMAR for statistical calculations. Results Of the 27 patients, 17 (63%) were male. Nine (33.3%) of the 27 patients had bilateral CNV. At presentation, CNV was active in 22 (61.1%) eyes and regressed in 14 (28.9%) eyes. All active CNV cases were 'classic' type, with the majority (80.5%) being subfoveal. The mean greatest linear dimension (GLD) was 3.16 ± 1.94 mm (range, 0.9-10.15). The most common cause (41.7%) was post-inflammatory. The mean duration to regression in treated eyes was 103.53 days (15 eyes). Recurrence was noted in three (8.3%) eyes. The mean duration to first recurrence was 260 days (range, 90-390), and the mean follow-up duration was 779.53 ± 988.00 days. Conclusion CNV remains a cause of significant visual decline in children and adolescents. Male predominance, postinflammatory etiology, bilateral affection, and subfoveal location are noteworthy, with a high regression rate in response to treatment. Re-treatment is required in a limited number of cases.

show abstract

“…CNV membrane removal in AMD patients appears to be associated with removal of native RPE cells and photoreceptors leading to loss of visual function 48 . Furthermore, there is a high-rate of recurrences (up to 46%) and complications 47,[49][50][51] .…”

Section: Available Treatments For Amdmentioning

confidence: 99%

Benzoporphyrin (verteporfin) photodynamic therapy for choroidal neovascularization in age-related macular degeneration

Lucena¹,

Miller²

2000

Arq. Bras. Oftalmol.

View full text Add to dashboard Cite

Purpose: To review and discuss the available treatments for choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) emphasizing to photodynamic therapy (PDT).Methods: Published papers from 1974 until 1999 related to AMD, its available treatments and PDT were reviewed.Results: The most used effective treatment for CNV is laser photocoagulation which does not have a major impact on the blindness due to AMD.

show abstract

Biomicroscopic and Histopathologic Considerations Regarding the Feasibility of Surgical Excision of Subfoveal Neovascular Membranes

Cited by 319 publications

References 15 publications

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents

Choroidal neovascularization in 36 eyes of children and adolescents

Benzoporphyrin (verteporfin) photodynamic therapy for choroidal neovascularization in age-related macular degeneration

Contact Info

Product

Resources

About